organicell™ REGENERATIVE MEDICINE
COVID-19 STATEMENT
Organicell™ has recently received an approval notification from the FDA for its investigational new drug (IND) application investigating their lead product, Organicell™ Flow, for patients diagnosed with moderate to severe acute respiratory syndrome (SARS) due to COVID-19 infection. This trial will be the first randomized, double-blinded, placebo-controlled, phase I/II multi-center clinical trial investigating the safety and potential efficacy of perinatal sourced components for COVID-19.
Organicell™ is the leading, fully integrated Regenerative Medicine Company. Our world class research, technology, manufacturing, and clinical development team is focused on creating new regenerative medicine.
We believe that our ground-breaking research in the field of nanotechnology, specifically extracellular vesicles and perinatal-derived nanoparticles, is the next frontier of regenerative therapeutics. Organicell™ is committed to creating life changing and lifesaving therapies for patients.
The Next Generation of
Biologic Medicine
Organicell™ is the leading, fully integrated Biologic Medicine Company. Our world class research, technology, manufacturing and clinical development team is focused on creating new biologic medicine.
We believe that our ground-breaking research in the field of nanotechnology, specifically extracellular vesicles and perinatal-derived nanoparticles, is the next frontier of cell-based regenerative therapeutics. Organicell™ is committed to creating life changing and lifesaving therapies for patients.
therapeuticsorganicell™ BIOLOGICS
Our MISSION
Our mission is to transform regenerative medicine by continuing to combine nano- technology with other synergistic therapies and become the healthcare incubator for biologic medicine.
The Organicell™ Difference
- Isolating the therapeutic signals released by regenerative cells, and using them rather than the cells themselves are the next generation as a therapy.
- Targeted cells will react to these messaging signals and will change their behavior accordingly. There is a tremendous therapeutic potential of extracellular vesicles and nano-particles.
- Organicell™ Flow & Organicell™ Factor X are NOT culture expanded
- Patent Pending Technology
- Ongoing Clinical Trials
We believe we have found the key to consistent patient outcomes
